Navigation Links
NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Date:9/21/2007

bsequent 12-week study period.

Anthony A. DiTonno, President and CEO, commented, "I am very pleased with our ability to complete the enrollment of this study ahead of plan. When we completed our initial public offering earlier this year, we indicated that we would file a new drug application (NDA) with the Food and Drug Administration (FDA) in the second half of 2008. Completion of enrollment in this study, on top of our three already completed successful Phase 3 trials, increases our confidence that we can meet this goal."

NeurogesX has successfully completed two Phase 3 studies in postherpetic neuralgia (PHN) and one in HIV-DSP. NGX-4010 has been granted orphan status and has received fast track designation from the FDA for HIV-DSP. NeurogesX believes that it is on track to file for marketing approval in the European Union before the end of 2007 for a broad indication of peripheral neuropathic pain. The Company is currently evaluating various regulatory filing strategies in the United States in order to most efficiently seek FDA approval of both the PHN and HIV-DSP indications, and believes that it will be able to submit a new drug application with the FDA in 2008.

About PHN and HIV-DSP

PHN is a painful condition affecting sensory nerve fibers. It is a complication of shingles, a second outbreak of the varicella-zoster virus, which initially causes chickenpox. Following an initial infection, some of the virus can remain dormant in nerve cells. Years later, age, illness, stress, medications or other factors that are not well understood can lead to reactivation of the virus. The rash and blisters associated with shingles usually heal within six weeks, but some people continue to experience pain for years thereafter. This pain is known as postherpetic neuralgia. PHN may occur in almost any area, but is especially common on the torso.

HIV-DSP is caused primarily by three factors: direct activation of cells known as sensory neurons by the
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... PUNE, India , September 4, 2015 /PRNewswire/ ... Industry, 2015 Market Research Report is a professional ... the global Surgical Gown industry with a focus ... will take 2-3 working days once an order ... gown market spread across 150 pages, analyzing and ...
(Date:9/4/2015)... 4, 2015 According to a ... Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Billion by 2020, growing at a CAGR of 11.2% ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)...  Cumberland Pharmaceuticals (CPIX), today announced that A.J. Kazimi ... on September 10, 2015. DATE: Thursday, September ... http://tinyurl.com/sep10pre This will be a ... ask the company questions in real-time - both in ... trade booth." If attendees are not able to join ...
Breaking Medicine Technology:Surgical Gown Market 2020 Forecasts With a Focus on China 2Surgical Gown Market 2020 Forecasts With a Focus on China 3Surgical Gown Market 2020 Forecasts With a Focus on China 4Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com September 10 2
... - Phase 2 trial expected to begin in late ... June 4 Nuvelo, Inc.,(Nasdaq: NUVO ) today ... a,single-center, Phase 1b trial to determine the safety, tolerability ... direct,thrombin-inhibiting aptamer, in approximately 30 healthy male volunteers., ...
... at American Society of Clinical Oncology meeting indicate ... compared to historical data., PRINCETON, N.J., June ... CPX-1 Phase 2 clinical trial in patients,with advanced ... and floxuridine, based on the company,s proprietary,CombiPlex(TM) technology. ...
Cached Medicine Technology:Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 2Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 3Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 3
(Date:9/4/2015)... ... September 04, 2015 , ... Keeping mold top of mind is important ... quite common. Mold can grow anywhere - on carpet, clothing, food, paper, and even ... moisture and water in the home is key to preventing mold growth, which if ...
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, a ... announced its only mission and research focus: Water Life Science®. In the current ... water evaporation is becoming dangerously accelerated. As a result of the global fresh ...
(Date:9/4/2015)... New York, NY (PRWEB) , ... September 04, 2015 , ... ... 400 meters qualifying heat, and followed up with victory in the men’s 400 meters ... Caribbean (NACAC) Senior Track and Field Championships in San Jose, Costa Rica in August ...
(Date:9/4/2015)... ... 04, 2015 , ... EMED Jamaica Global Ltd. (EMED), Jamaica’s ... entered into a multi-year agreement with Health City Cayman Islands. , ( http://www.healthcitycaymanislands.com ... American healthcare, Jamaican healthcare and Health City Cayman Islands to deliver high-quality, affordable ...
(Date:9/3/2015)... ... , ... TransPack Toon gives users a set of 90 cartoon transitions for ... in 30 different styles. Presets range from snow, underwater, forest, futuristic, city and many ... features 90 cartoon transitions from 30 unique styles. Editors can choose between line ...
Breaking Medicine News(10 mins):Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2
... Shelves for Father,s Day , , NEW YORK, June 8 ... pain may lie in a $59.99 biomechanically-engineered foam and rubber flip-flop ... for the sixty million adults who reported persistent back pain last ... be a medical breakthrough is now available in the Dass, a ...
... , BALTIMORE, June 8 Metastorm, a leading provider ... and Enterprise Architecture (EA) software for aligning strategy with ... customer Wyeth Pharmaceuticals as one of this year,s CIO ... Wyeth is one of the world,s largest pharmaceutical and ...
... Factor Driving the Market Decline Will be Singulair,s Loss ... Decision Resources , , WALTHAM, Mass., June 8 ... and advisory firms for pharmaceutical and healthcare issues, finds ... and cost consciousness will reduce the asthma drug market ...
... Cedars-Sinai Outpatient Cancer Center Appointed COO , , ... today announced the appointment of Paul R. O,Dea to ... formerly Vice President, Aptium Oncology and Executive Director, Cedars-Sinai ... hospital-based cancer centers. The appointment was effective June 1, ...
... LOMBARD, Ill., June 8 A major session at the ... Conference will focus on how supply chains are helping to ... will be held September 20-23 in Chicago, Illinois. , ... improving delivery of drugs, vaccines, and other remedies to needy ...
... More Efficient Operation for Gateway Healthcare , , ... announced today that it is addressing the ... with the unique, next generation voice product, Cox ... moved its telecommunications services from a competitive provider to ...
Cached Medicine News:Health News:One of Women's Best Kept Secrets is Now Available in the Men's Department 2Health News:Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project 2Health News:Generic Erosion, Increased Competition and Cost Consciousness Will Reduce Overall Asthma Drug Market by $1.8 Billion from 2008 to 2018 2Health News:Aptium Oncology Names New Chief Operating Officer 2Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 2Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 3Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 4
... a unique and versatile posterior spinal implant ... as a translational implant in correction of ... for bone or metallic implants, cables have ... configurations. Songer Cables offer advantages in strength, ...
Demineralized bone matrix dispensed in a jar. Fibers will be free of foreign matter. Glycerol 70-88% by weight. Calcium content less than 8%....
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%....
... matrix and conductive cancellous chips. ... be free of foreign matter. ... is 125 to 1000 . ... 1 - 8 mm. 5:3 ...
Medicine Products: